User:Abijith Reddy/sandbox

Laxai Life Sciences is an Indian advanced drug discovery and contract research solutions organisation established in 2007 with a vision to innovate and accelerate the drug discovery campaigns of global pharmaceutical companies, focused on oncology and inflammatory diseases, Aurigene has applied it deep target and therapeutic area expertise, gained from the experience of multiple programs, to deliver small molecule drug candidates to its biotech and pharmaceutical partners.. The goal of Laxai is to provide intelligent solutions to global pharmaceutical and biotechnological companies by providing high-quality services with accelerated timelines.

Laxai has pioneered a unique model of drug discovery collaborations with large-pharmaceutical, mid-pharmaceutical companies and Biotechs, in addition, Laxai has also developed a pipeline of assets for licensing in oncology and inflammatory diseases.

Contents:

In 2007, Vamsi Madddipatla was elected as the CEO, spearheading the organization into new heights.

In 2008, the company forayed into manufacturing services, partnering with Contract Manufacturing Organisation (CMO) for scale up and large scale API development

In 2010, the company started its drug discovery services, parterning with Celgene and rolled out a Clinical Candidate. Laxai succeeded in several such programs, there were programs with Avila Therapeutics, Aptose Bioscinces

andBioimics AB to name a few

In 2016, Laxai started its biology division with novel scientific project in the Biosimilars domain

In 2017, the company has yet again forayed into novel large molecule therapeutics with Oligonucleotides and Peptides.